Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Increase in Short Interest

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 6,851,192 shares, an increase of 28.4% from the December 15th total of 5,336,430 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average daily volume of 1,852,007 shares, the short-interest ratio is currently 3.7 days. Based on an average daily volume of 1,852,007 shares, the short-interest ratio is currently 3.7 days. Approximately 2.6% of the company’s stock are sold short.

Insiders Place Their Bets

In other news, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the sale, the executive vice president directly owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This represents a 47.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the transaction, the director directly owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 231,856 shares of company stock valued at $2,743,724. 26.56% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Spire Wealth Management boosted its holdings in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the last quarter. Comerica Bank lifted its holdings in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth $31,000. Focus Partners Wealth bought a new stake in shares of Amneal Pharmaceuticals in the third quarter worth $42,000. Finally, Advisory Services Network LLC bought a new stake in shares of Amneal Pharmaceuticals in the third quarter worth $50,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Trading Up 1.7%

AMRX stock opened at $13.41 on Friday. The stock has a market capitalization of $4.22 billion, a PE ratio of 670.84 and a beta of 1.34. Amneal Pharmaceuticals has a 12-month low of $6.68 and a 12-month high of $13.48. The stock’s 50 day simple moving average is $12.42 and its 200 day simple moving average is $10.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The firm had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, research analysts predict that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and set a $13.00 target price (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price objective for the company. Finally, Truist Financial set a $15.00 target price on Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $13.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.